Our patient was considered to be at high risk for thrombosis because of his age >60 years, history of stroke and diabetes, and the JAK2 V617F mutation, which should be treated with a combination of low-dose ASA and hydroxyurea. This evidence concerns the gene JAK2 and stroke disorder.